<?xml version="1.0" ?>
<GlossaryTerm id="CDR0000756463">
  <TermName>amatuximab</TermName>
  <TermPronunciation>(A-muh-TUK-sih-mab)</TermPronunciation>
  <TermDefinition>
    <DefinitionText>A substance being studied in the treatment of mesothelioma. Amatuximab binds to a protein called mesothelin, which is found on some cancer cells. Amatuximab may help the immune system kill cancer cells. It is a type of monoclonal antibody. Also called anti-mesothelin monoclonal antibody MORAb-009 and MORAb-009.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </TermDefinition>
  <MediaLink ref="CDR0000760882" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;amatuximab&quot;" language="en" id="_3"/>
  <MediaLink ref="CDR0000760881" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;amatuximab&quot;" language="es" id="_4"/>
  <SpanishTermName>amatuximab</SpanishTermName>
  <SpanishTermDefinition>
    <DefinitionText>Sustancia en estudio para el tratamiento del mesotelioma. El amatuximab se une a una proteína llamada mesotelina, que se encuentra en algunas células cancerosas. El amatuximab podría ayudar al sistema inmunitario a destruir células cancerosas. Es un tipo de anticuerpo monoclonal. También se llama anticuerpo monoclonal MORAb-009 antimesotelina y MORAb-009.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </SpanishTermDefinition>
  <DateFirstPublished>2014-03-10</DateFirstPublished>
  <DateLastModified>2014-03-10</DateLastModified>
</GlossaryTerm>
